Biotechnology companies apply biological science to develop products, services and technologies that address challenges in healthcare, agriculture, industry and environmental sustainability.
This category includes companies working on:
Browse 360 UK biotechnology companies below.
Historical gene therapy platform targeting cancer stem cells
Cellinta was a University of Edinburgh-linked biotechnology company established to develop selective gene therapies targeting cancer stem cells in solid tumours. Its approach used stem-cell-specific regulatory sequences to restrict therapeutic gene expression to tumour-driving cell populations. The technology…
Cell-based platform for next-generation mRNA medicines
Sensible Biotechnologies is a biotechnology company developing a cell-based platform for the design, optimisation, and manufacturing of high-quality mRNA. Using engineered living cells and precision fermentation, the platform produces low-immunogenicity mRNA at scale, addressing fundamental limitations of conventional…
Individualised neoantigen-based cell therapies for ovarian and solid cancers
Singula Bio is a seed-stage biotechnology company developing individualised, neoantigen-based cell therapies for patients with solid tumours, with an initial focus on ovarian cancer and other difficult-to-treat malignancies. The company's approach harnesses a patient's own immune system to target mutations that appear…
Plasmonic PCR diagnostics for rapid infectious disease detection
RapidX Bio is a biotechnology company developing point-of-care molecular diagnostics for infectious diseases. Its plasmonic PCR technology uses light-responsive gold nanorods to accelerate nucleic acid amplification and reduce sample preparation requirements. The company is developing portable tests to identify…
Biomimetic cell culture platform for reproducible cell therapy development
Stembond Technologies is a Cambridge University spin-out developing a synthetic, mechanically tuned biomimetic substrate that replicates the physical properties of human tissue microenvironments. The platform delivers reproducible cell culture conditions, reducing phenotypic drift and improving consistency across…
Targeted transcriptomic sequencing services for diagnostics and drug discovery
BioClavis is a genomics R&D and services laboratory leveraging their targeted RNA sequencing platform for high-throughput transcriptomic and biomarker analysis. The platform enables customisable gene expression profiling from crude cell lysates and archival FFPE tissue without nucleic acid purification, making it…
Microbiome emulation platform for drug development de-risking
BioCorteX is a biotech company that applies computational emulation to model interactions between drugs, the human microbiome, and the immune system. Its platform uses physics- and chemistry-based simulation to generate in-silico predictions of drug-bacteria interactions across diverse patient populations. The…
Longer-lasting RNA medicines and immune-stealthed CAR-T research
Cambridge RNA Technologies develops experimental RNA platforms intended to extend the duration of therapeutic gene expression. Its research includes technologies for longer-lasting RNA medicines. In collaboration with Anglia Ruskin University, the company has investigated immune-stealth approaches for donor-derived…
Fragment-based drug discovery platform for oncology and CNS disorders
Astex Pharmaceuticals is a drug discovery and development company pioneering fragment-based drug discovery through its proprietary Pyramid platform, applied to oncology and central nervous system disorders. Astex maintains an internal pipeline alongside active collaborations with MSD targeting KRAS and p53. The…
Engineered probiotic bacteria producing peptide therapeutics inside the body
Hijack Bio develops engineered probiotic bacteria designed to produce and release peptide therapeutics inside the body. The synthetic biology approach aims to reduce reliance on conventional external manufacturing and cold-chain distribution while enabling oral delivery of peptide drugs. Potential applications include…
CRISPR-engineered tumour-infiltrating lymphocyte therapy
Intima Bioscience is a clinical-stage biotechnology company developing CRISPR gene-edited tumour-infiltrating lymphocyte therapies for solid tumours. Its platform targets CISH, an intracellular immune checkpoint that suppresses T cell activity against tumours; CRISPR knockout of CISH in patient-derived TILs enhances…
Fragment-based drug discovery with a glioblastoma focus
IOTA Pharmaceuticals is a Cambridge drug discovery company specialising in fragment-based design, molecular screening and computational approaches to early-stage therapeutics. Its research combines transcriptomics, phenotypic assays and natural product screening to investigate candidate treatments. A major focus is…
AI-guided RNA therapies for chronic metabolic diseases
Elarna Bio is a biotechnology company developing long-acting RNA therapeutics for chronic metabolic diseases. It combines AI-driven discovery with RNA engineering to improve the duration of therapeutic activity. The platform focuses on challenges associated with liver-targeted RNA treatments and is intended for…
AI-driven platform engineering better crop varieties
Wild Bioscience is an agricultural biotechnology company developing next-generation crop varieties using a platform that combines evolutionary biology with machine learning. By mining genetic variation in wild plant relatives, the company identifies and designs gene edits targeting traits including nitrogen use…
RNA therapeutics platform targeting multiple disease pathways
SymphoRNA is a company developing RNA medicines designed to address complex diseases by targeting multiple biological pathways simultaneously. Its platform uses a polysaccharide-based delivery system to enable combination RNA therapies, with the aim of achieving outcomes that single-target approaches cannot. Spun out…
Targeted small-molecule drugs for brain and metastatic cancers
Sentinel Oncology is a biotechnology company developing targeted small-molecule drugs for difficult-to-treat cancers. Its medicinal chemistry programmes investigate DNA damage responses and cell division. Some candidates are designed to cross the blood-brain barrier, targeting primary brain tumours and cancers that…
Engineered macrophage cell therapy for inflammatory and fibrotic disease
Resolution Therapeutics is a clinical-stage biotech developing regenerative macrophage therapies for inflammatory and fibrotic diseases. Its platform harnesses the tissue-repairing properties of macrophages, engineering them to deliver anti-fibrotic and anti-inflammatory effects at sites of organ damage. The lead…
Programmable RNA delivery platform targeting non-hepatic tissues
Sixfold Bioscience is a biotechnology company developing a programmable RNA-based delivery platform that exploits the body's natural extracellular RNA transport pathways to direct therapeutic RNA molecules to specific non-hepatic tissues and cell types. The platform uses computationally designed chemical modifications…
AI-driven robotic chemistry platform for on-demand molecule synthesis
Chemify is a UK deep-tech company that digitises chemical synthesis by combining a proprietary chemistry programming language, robotics, and artificial intelligence. Its platform translates digital molecular designs into physical compounds, drawing on a large curated database of validated chemical reactions to…
Animal genetics company applying genomics and gene editing to livestock
Genus plc specialises in the genetic improvement of livestock through genomic selection and gene editing. Its commercial divisions supply semen and embryos from elite cattle and genetically superior breeding pigs to producers globally. Its R&D programme applies CRISPR-based precision breeding to improve disease…